Immunotherapy for acute myeloid leukemia

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 207-214

  Lichtenegger, Felix S ^a,b   Krupka, Christina ^a,b   Köhnke, Thomas ^a,b   Subklewe, Marion ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Clinical Co operation Group Immunotherapy at the Helmholtz Institute Munich   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 330; BLINATUMOMAB; CD33 CHIMERIC ANTIGEN RECEPTOR ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; GEMTUZUMAB OZOGAMICIN; LEY CHIMERIC ANTIGEN RECEPTOR ANTIBODY; MGD 006; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; SGN CD33A; UNCLASSIFIED DRUG; ANTIBODY;

ACTIVE IMMUNIZATION; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; RECURRENT DISEASE; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; RECURRENCE; T-LYMPHOCYTES;

EID: 84937422742     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.03.006     Document Type: Review

References (84)

1. Siegbeel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Visser O., Trama A., Maynadié M., et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012, 48:3257-3266.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site. 2014. http://seer.cancer.gov/csr/1975_2011/.
4. Doria-Rose V.P., Harlan L.C., Stevens J., Little R.F. Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program. Leuk Lymphoma 2014, 55:2549-2555.
5. Burnett A., Wetzler M., Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
6. Kantarjian H., O'brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
7. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
8. Forman S.J., Rowe J.M. The myth of the second remission of acute leukemia in the adult. Blood 2013, 121:1077-1082.
9. Gale R.P., Wiernik P.H., Lazarus H.M. Should persons with acute myeloid leukemia have a transplant in first remission?. Leukemia 2014, 28:1949-1952.
10. Stelljes M., Krug U., Beelen D.W., et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014, 32:288-296.
11. Klepin H.D., Rao A.V., Pardee T.S. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol 2014, 32:2541-2552.
12. Yates J.W., Wallace H.J., Ellison R.R., Holland J.F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973, 57:485-488.
13. Büchner T., Schlenk R.F., Schaich M., et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012, 30:3604-3610.
14. Anguille S., Van Tendeloo V.F., Berneman Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012, 26:2186-2196.
15. Powles R.L., Crowther D., Bateman C.J., et al. Immunotherapy for acute myelogenous leukaemia. Br J Cancer 1973, 28:365-376.
16. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
17. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
18. Lichtenegger F.S., Schnorfeil F.M., Hiddemann W., Subklewe M. Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy 2013, 5:63-78.
19. Ruben J.M., Visser L.L., Bontkes H.J., et al. Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. Immunotherapy 2013, 5:859-868.
20. Vasu S., Blum W. Emerging immunotherapies in older adults with acute myeloid leukemia. Curr Opin Hematol 2013, 20:107-114.
21. Tettamanti S., Magnani C.F., Biondi A., Biagi E. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors. Immunol Lett 2013, 155:43-46.
22. Arpinati M., Curti A. Immunotherapy in acute myeloid leukemia. Immunotherapy 2014, 6:95-106.
23. Martner A., Thorén F.B., Aurelius J., Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Rev 2013, 27:209-216.
24. Krupka C., Kufer P., Kischel R., et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014, 123:356-365.
25. Bross P.F., Beitz J., Chen G., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001, 7:1490-1496.
26. Petersdorf S.H., Kopecky K.J., Slovak M., et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121:4854-4860.
27. Burnett A.K., Hills R.K., Milligan D., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011, 29:369-377.
28. Hills R.K., Castaigne S., Appelbaum F.R., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014, 15:986-996.
29. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005, 19:176-182.
30. Kung Sutherland M.S., Walter R.B., Jeffrey S.C., et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013, 122:1455-1463.
31. Ehninger A., Kramer M., Röllig C., et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 2014, 4:e218.
32. Nguyen D.H., Ball E.D., Varki A. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol 2006, 34:728-735.
33. Lapusan S., Vidriales M.B., Thomas X., et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012, 30:1121-1131.
34. Borthakur G., Rosenblum M.G., Talpaz M., et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 2013, 98:217-221.
35. Jurcic J.G., Dhillon S. Targeted alpha-particle immunotherapy with bismuth-213 and actinium-225 for acute myeloid leukemia. J Postgrad Med Educ Res 2013, 47:14-17.
36. Laszlo G.S., Estey E.H., Walter R.B. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 2014, 28:143-153.
37. Baeuerle P.A., Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009, 69:4941-4944.
38. Mack M., Gruber R., Schmidt S., Riethmüller G., Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 1997, 158:3965-3970.
39. Löffler A., Kufer P., Lutterbüse R., et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
40. Kufer P., Mack M., Gruber R., Lutterbüse R., Zettl F., Riethmüller G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 1997, 45:193-197.
41. Topp M.S., Kufer P., Gökbuget N., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
42. Topp M.S., Gökbuget N., Zugmaier G., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012, 120:5185-5187.
43. Handgretinger R., Zugmaier G., Henze G., Kreyenberg H., Lang P., von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011, 25:181-184.
44. Bargou R., Leo E., Zugmaier G., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
45. Friedrich M., Henn A., Raum T., et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 2014, 13:1549-1557.
46. Laszlo G.S., Gudgeon C.J., Harrington K.H., et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014, 123:554-561.
47. Abdool A., Yeh C.-H., Kantarjian H., et al. Circulating CD33 and its clinical value in acute leukemia Experimental. Hematology 2010, 38:462-471.
48. Kikushige Y., Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann N Y Acad Sci 2012, 1266:118-123.
49. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
50. Arndt C., von Bonin M., Cartellieri M., et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013, 27:964-967.
51. Rader C. DARTs take aim at BiTEs. Blood 2011, 117:4403-4404.
52. Moore P.A., Zhang W., Rainey G.J., et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011, 117:4542-4551.
53. Testa U., Pelosi E., Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014, 2:4.
54. Hussaini A.L., Ritchey J., Rettig M.P., et al. Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs) [abstract]. ASH Annual Meeting Abstracts 2013, 122:360.
55. Arndt C., Feldmann A., von Bonin M., et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 2014, 28:59-69.
56. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989, 86:10024-10028.
57. Brentjens R.J., Davila M.L., Riviere I., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5. 177ra38.
58. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
59. Davila M.L., Riviere I., Wang X., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014, 6. 224ra25.
60. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
61. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
62. Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014, 33:540-549.
63. Ramos C.A., Savoldo B., Dotti G. CD19-CAR trials. Cancer J 2014, 20:112-118.
64. Maus M.V., Grupp S.A., Porter D.L., June C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123:2625-2635.
65. Marin V., Pizzitola I., Agostoni V., et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010, 95:2144-2152.
66. Dutour A., Marin V., Pizzitola I., et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012, 2012:683065.
67. Tettamanti S., Marin V., Pizzitola I., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013, 161:389-401.
68. Pizzitola I., Anjos-Afonso F., Rouault-Pierre K., et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014, 28:1596-1605.
69. Gill S., Tasian S.K., Ruella M., et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014, 123:2343-2354.
70. Tettamanti S., Biondi A., Biagi E., Bonnet D. CD123 AML targeting by chimeric antigen receptors: a novel magic bullet for AML therapeutics?. Oncoimmunology 2014, 3:e28835.
71. Wang Q.S., Wang Y., Lv H.Y., et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 2014, 23:184-191.
72. Mardiros A., Dos Santos C., McDonald T., et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia. Blood 2013, 122:3138-3148.
73. Ritchie D.S., Neeson P.J., Khot A., et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013, 21:2122-2129.
74. Uttenthal B., Martinez-Davila I., Ivey A., et al. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 2014, 164:366-375.
75. Berlin C., Kowalewski D.J., Schuster H., et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 2014, 29:647-659.
76. Skalova K., Mollova K., Michalek J. Human myeloid dendritic cells for cancer therapy: does maturation matter?. Vaccine 2010, 28:5153-5160.
77. Lichtenegger F.S., Mueller K., Otte B., et al. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One 2012, 7:e44266.
78. Ruben J.M., van den Ancker W., Bontkes H.J., et al. Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer Immunol Immunother 2014, 63:335-345.
79. Van Tendeloo V.F., Van de Velde A., Van Driessche A., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010, 107:13824-13829.
80. Berneman Z.N., Van de Velde A., Anguille S., et al. WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. J Clin Oncol (ASCO Annual Meeting Proceedings) 2012, 30:2506.
81. Subklewe M., Geiger C., Lichtenegger F.S., et al. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol Immunother 2014, 63:1093-1103.
82. Alatrash G., Molldrem J.J. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol 2011, 4:37-50.
83. Smits E.L., Lee C., Hardwick N., et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol Immunother 2011, 60:757-769.
84. Anguille S., Willemen Y., Lion E., Smits E.L., Berneman Z.N. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012, 14:647-656.